Chloroxoquinoline Capsules | Lung Cancer

Chloroxoquinoline Capsules Application Scope

Chloroxoquinoline Capsules are indicated for the treatment of breast cancer, non-small cell lung cancer, and other tumors.

Chloroxoquinoline Capsules Characteristics

• Ingredients: Chloroxoquinoline.
• Properties: The contents of the capsule are white or off-white crystalline powder.
• Specification: Each capsule contains 0.2 grams of Chloroxoquinoline.
• Packaging Specification: 0.2 grams × 45 capsules per box.
• Storage: Store in a sealed container at room temperature, protected from light.
• Expiry Date: 36 months.
• Executive Standard: National Drug Standard WS1-(X-052)-2006Z.
• Approval Number: National Drug Approval Number H20030359.
• Date of Revision: August 23, 2007.
• Manufacturer: Tonghua Maoxiang Pharmaceutical Co., Ltd.

Guidelines for Use Chloroxoquinoline Capsules

• Dosage and Administration: Administer orally at a dose of 20–30 mg per kilogram of body weight, divided into three doses daily. A continuous course of 4 weeks constitutes one treatment cycle.
• Adverse Reactions: The main adverse reactions include gastrointestinal discomfort, loss of appetite, nausea, vomiting, and reductions in white blood cells and hemoglobin.

Medication Limitations

• Contraindications: Contraindicated in individuals with known hypersensitivity to any component of the product.
• Precautions: Long-term use requires regular monitoring of blood counts and liver function.

Chloroxoquinoline Capsules Drug Interactions

• Drug Interactions: This product has central nervous system depressant effects; when used concurrently with other central depressant drugs, their dosages should be appropriately reduced. Additionally, this product induces liver enzymes, which may lead to drug interactions.